The world of probiotics is undergoing a paradigm shift, and it's all about traceability and functionality. At the Growth Asia Summit 2026, Lucas Chang, R&D Manager (Human Microbiome) at TCI, made a compelling argument that the next frontier of probiotics is not just about delivering microbes, but about understanding and addressing the complex biological challenges they face. This shift in perspective is particularly fascinating, as it challenges the traditional view of probiotics as mere logistics solutions. Instead, Chang emphasizes the importance of tracing the 'evidence chain' - the microbiome function, bioactive compounds, host response, and measurable impact - to truly understand the probiotic's mechanism of action. This is especially crucial when discussing healthy aging, as the body's response to pressure and biological challenges changes over time. One of the key insights from Chang's presentation is the idea that biology does not decline at a constant speed. Instead, there are specific 'checkpoints' where the body faces major disruptions, such as around the ages of 40 and 60. These transitions are marked by shifts in lipid metabolism, alcohol metabolism, cardiovascular health, immune regulation, and carbohydrate metabolism. This raises a deeper question: how can we optimize our bodies to handle these challenges and promote healthy aging? Chang highlights the importance of resilience, which lies in the space between two biological challenges. This perspective shifts the focus from simply avoiding aging to understanding how our bodies can handle the heat and recover from it. In terms of probiotic development, Chang introduces the concept of 'functionality' - designing probiotics that not only survive but also perform specific jobs after arrival. This changes the order of product design, starting with the desired health outcome and tracing the biology backwards to define the microbial job. TCI's patented probiotic strain, TCR711 (Bacillus coagulans TCI711), is a prime example of this approach. In a study involving adults with non-alcohol fatty liver disease (NAFLD), TCR711 improved liver-fat outcome by 8.7% compared to placebo. The interesting finding was that the gut ecology also shifted, suggesting that the probiotic's effect on the liver was not isolated but part of a broader ecosystem. This highlights the importance of understanding the gut-axis and the interconnectedness of different body systems. Chang also showcases the application of TCI's probiotic in liquid chocolate format, which not only helps with survival but also builds consumers' daily habits. This format offers a low free-water, lipid-rich phase, and reduced exposure to moisture and oxygen, making it a strain-compatible environment. The liquid chocolate probiotic is designed for everyday moments, offering a convenient and tasty way to incorporate probiotics into one's diet. In conclusion, the paradigm shift in probiotics is about moving beyond logistics to understanding and addressing biological challenges. This requires a shift in perspective, from viewing the gut as a digestive organ to understanding it as a complex ecosystem with interconnected functions. By embracing this new approach, we can unlock the full potential of probiotics and promote healthy aging through targeted interventions and everyday habits.
